Expert Review of Cardiovascular Therapy最新文献_第5页

Clinical implications of combination proton pump inhibitor and triple therapies in patients with atrial fibrillation following percutaneous intervention: a guide for clinicians. 经皮介入治疗后心房颤动患者联合使用质子泵抑制剂和三联疗法的临床意义：临床医师指南。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-09-01 Epub Date: 2024-09-12 DOI: 10.1080/14779072.2024.2401865

Jacob J Gries, Bing Chen, Hafeez Ul Hassan Virk, Umair Khalid, Hani Jneid, Yochai Birnbaum, Carl J Lavie, Chayakrit Krittanawong

{"title":"Clinical implications of combination proton pump inhibitor and triple therapies in patients with atrial fibrillation following percutaneous intervention: a guide for clinicians.","authors":"Jacob J Gries, Bing Chen, Hafeez Ul Hassan Virk, Umair Khalid, Hani Jneid, Yochai Birnbaum, Carl J Lavie, Chayakrit Krittanawong","doi":"10.1080/14779072.2024.2401865","DOIUrl":"10.1080/14779072.2024.2401865","url":null,"abstract":"Introduction: Patients on systemic oral anticoagulation with vitamin K antagonists (VKA) or non-vitamin K oral anticoagulants (NOAC) often require triple therapy following percutaneous coronary intervention, substantially increasing the risk of bleeding. Gastroprotective agents like proton pump inhibitors (PPI) are often employed to mitigate this risk, despite potential competitive inhibition between P2Y12-receptor inhibitors, NOACs, and VKAs. While the interactions and clinical outcomes of PPIs and DAPT have been frequently explored in literature, not many studies have evaluated the same outcomes for triple therapy.Areas covered: This comprehensive narrative review of three studies on PPIs and triple from the PubMed/MEDLINE database supplemented by 23 other relevant studies aims to use the available literature to analyze the potential interactions between PPIs and triple therapy while shedding light on their mechanisms, clinical implications, and areas for optimization.Expert opinion: If triple therapy is indicated following PCI, then patients at high-risk for bleeding may benefit from transition to apixaban and a PPI to lower the risk of gastrointestinal bleeding. More research is needed to determine the role of PPIs in triple therapies in prevention of gastrointestinal bleeding or potentiation of other adverse outcomes.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"483-491"},"PeriodicalIF":1.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence and predictors of acute coronary syndrome after transcatheter mitral valve repair. 经导管二尖瓣修复术后急性冠状动脉综合征的发病率和预测因素。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-09-01 Epub Date: 2024-09-19 DOI: 10.1080/14779072.2024.2398443

Mishita Goel, Irfan Shafi, Adel Elmoghrabi, Karthik Ramaseshan, Mohammed M Uddin, Nasser Lakkis, Chadi Alraies

{"title":"Incidence and predictors of acute coronary syndrome after transcatheter mitral valve repair.","authors":"Mishita Goel, Irfan Shafi, Adel Elmoghrabi, Karthik Ramaseshan, Mohammed M Uddin, Nasser Lakkis, Chadi Alraies","doi":"10.1080/14779072.2024.2398443","DOIUrl":"10.1080/14779072.2024.2398443","url":null,"abstract":"Background: Acute coronary syndrome (ACS) post-transcatheter mitral valve repair (TMVR) carries high mortality. We aim to study the incidence and predictors of ACS in patients who underwent TMVR.Research design and methods: We queried the U.S. National Readmission Database to identify all cases of TMVR from 2016 to 2019. We further evaluated the incidence of ACS and used multivariable logistic regression to determine independent predictors of ACS in this population.Results: Among 3,742 patients who underwent TMVR, 264 (7.05%) developed ACS. Among ACS patients, 204 (77%) had non-ST-segment elevation ACS and 66 (25%) had ST-segment elevation ACS. Independent predictors of ACS were acute limb ischemia, cardiogenic shock, history of coronary artery disease (CAD), smoking, cardiac arrest, respiratory failure requiring mechanical ventilation, and acute kidney injury. In-hospital mortality among ACS was three times higher in ACS patients than without ACS (16.76% vs. 5.45%, p-value < 0.01).Conclusions: ACS is not an uncommon complication after TMVR. The occurrence of ACS after TMVR is associated with high in-hospital mortality, longer length of stay, and higher hospital charges. The strongest predictors of ACS in these patients are the development of acute limb ischemia, cardiogenic shock, and a history of CAD.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"517-522"},"PeriodicalIF":1.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Linking head and heart health: the association between psychiatric outcomes for patients with major depressive disorder and myocardial ischemia - a systematic review. 将头部健康与心脏健康联系起来：重度抑郁症患者的精神状况与心肌缺血之间的关联--系统性综述。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-09-01 Epub Date: 2024-10-01 DOI: 10.1080/14779072.2024.2409434

Amanda Cardoso, Laiana Azevedo Quagliato, Natia Horato, Pablo Eduardo Pereira Dutra, Antonio Egidio Nardi

{"title":"Linking head and heart health: the association between psychiatric outcomes for patients with major depressive disorder and myocardial ischemia - a systematic review.","authors":"Amanda Cardoso, Laiana Azevedo Quagliato, Natia Horato, Pablo Eduardo Pereira Dutra, Antonio Egidio Nardi","doi":"10.1080/14779072.2024.2409434","DOIUrl":"10.1080/14779072.2024.2409434","url":null,"abstract":"Introduction: The development of depression after myocardial infarction is associated with a 2- to 2.5-fold increased risk of all-cause mortality, cardiovascular mortality, and cardiovascular events. The objective of this study was to investigate, through a broad search of the literature, whether major depression is associated with worse psychiatric outcomes in middle-aged patients with myocardial ischemia.Methods: An extensive search for studies on the association between major depression and myocardial ischemia was conducted in the PubMed, Embase, PsycINFO, and Web of Science databases. Randomized clinical trials of middle-aged patients with myocardial ischemia and concomitant depressive symptoms were included.Results: The 14 articles included in this systematic review did not confirm an association between myocardial ischemia and depression with worse psychiatric outcomes in middle-aged patients. However, worse cardiovascular outcomes have been observed in patients with depression after myocardial infarction.Conclusions: The findings of this study suggest that major depression increases cardiovascular risk in patients after acute myocardial infarction, possibly because of a more pronounced increase in inflammatory markers.Registration: This systematic review was registered in the International Prospective Registry of Systematic Reviews (PROSPERO) under the number CRD: 511650.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"509-516"},"PeriodicalIF":1.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PTSD and mood disorders in implantable cardioverter defibrillator patients: is more psychological assessment needed? 植入式心律转复除颤器患者的创伤后应激障碍和情绪障碍：是否需要更多心理评估？

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-08-01 DOI: 10.1080/14779072.2024.2385974

Anne Sorrell, Rebecca Harrell, Elizabeth Jordan, Maeve Sargeant, Rajasekhar Nekkanti, John N Catanzaro, Samuel F Sears

{"title":"PTSD and mood disorders in implantable cardioverter defibrillator patients: is more psychological assessment needed?","authors":"Anne Sorrell, Rebecca Harrell, Elizabeth Jordan, Maeve Sargeant, Rajasekhar Nekkanti, John N Catanzaro, Samuel F Sears","doi":"10.1080/14779072.2024.2385974","DOIUrl":"10.1080/14779072.2024.2385974","url":null,"abstract":"Introduction: The aim of this review is to identify common mood concerns in ICD patients and suggest brief psychological screeners essential for early detection and monitoring in patient care.Areas covered: Reliable and valid psychological assessment tools are reviewed, including those specifically designed for ICD patient populations.Expert opinion: Psychological assessment, in combination with cardiologic standard of care, can help overcome many barriers associated with poor implantable cardioverter-defibrillator (ICD) management and related cardiovascular outcomes. Earlier identification and treatment of mood concerns in ICD patients has been shown to improve quality of life (QOL) and patient outcomes. At this time, however, logistical challenges and time restraints, in addition to knowledge of appropriate treatment plans or referral options, remain central barriers to providing integrated, patient-centered care. Ultimately, all cardiology clinics would benefit from a collaborative care team that includes a mental health consultant or in-house psychologists who can provide consultations or referral services. Additionally, all patients that come to the clinics should complete proactive screening measures as routine component of care to assess the presence of mood concerns to improve patient outcomes and aid in treatment planning.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"347-352"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges and solutions to implementing cardiac rehabilitation in a low- and middle-income country. 在中低收入国家实施心脏康复的挑战和解决方案。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-16 DOI: 10.1080/14779072.2024.2379836

Abraham Samuel Babu, Vibha Bhat, Prinu Jose, Sebastian Padickaparambil, Ramachandran Padmakumar, Panniyammakal Jeemon

{"title":"Challenges and solutions to implementing cardiac rehabilitation in a low- and middle-income country.","authors":"Abraham Samuel Babu, Vibha Bhat, Prinu Jose, Sebastian Padickaparambil, Ramachandran Padmakumar, Panniyammakal Jeemon","doi":"10.1080/14779072.2024.2379836","DOIUrl":"10.1080/14779072.2024.2379836","url":null,"abstract":"Background: Cardiac rehabilitation (CR) remains greatly underutilized, especially in low- and middle-income countries (LMIC). It is therefore important to explore factors that contribute to this, as perceived by health-care professionals (HCPs).Research design and methods: This was a qualitative study using in-depth interviews that enrolled 18 HCPs (i.e. six each of physicians, physiotherapists, and nurses; mean experience in CR: 17.9 ± 11.8 yrs) working in cardiovascular care, and CR across private and government hospitals (both teaching and non-teaching) in India.Results: The main challenges were related to lack of referrals, perceived lack of benefit from CR, poor infrastructure within hospitals and health systems, and differences in practice. The perceived inadequacies were lack of competencies in CR, limited task sharing strategies, and ineffective utilization of existing human resources. Devising strategies to improve awareness and competencies, facilitating task sharing, and remodeling holistic care with an active CR component may be beneficial to facilitate greater implementation of CR in India.Conclusions: Challenges, inadequacies, and solutions to implementing CR have been explored by involving various HCPs commonly involved in delivering CR across different health systems in a LMIC.Trial registration: www.ctri.nic.in with identifier CTRI/2020/07/026807.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"421-428"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term outcomes following bioresorbable vascular scaffolds. 生物可吸收血管支架的长期疗效。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-30 DOI: 10.1080/14779072.2024.2375340

Kotaro Miyashita, Kai Ninomiya, Akihiro Tobe, Shinichiro Masuda, Nozomi Kotoku, Shigetaka Kageyama, Pruthvi C Revaiah, Tsung-Ying Tsai, Bo Wang, Scot Garg, Patrick W Serruys, Yoshinobu Onuma

{"title":"Long-term outcomes following bioresorbable vascular scaffolds.","authors":"Kotaro Miyashita, Kai Ninomiya, Akihiro Tobe, Shinichiro Masuda, Nozomi Kotoku, Shigetaka Kageyama, Pruthvi C Revaiah, Tsung-Ying Tsai, Bo Wang, Scot Garg, Patrick W Serruys, Yoshinobu Onuma","doi":"10.1080/14779072.2024.2375340","DOIUrl":"10.1080/14779072.2024.2375340","url":null,"abstract":"Introduction: The higher scaffold thrombosis rates observed with the first-generation bioresorbable scaffolds (BRSs) compared to conventional drug-eluting stents were likely due in part to bioresorbable polymers having insufficient radial strength, necessitating larger strut profiles. Meta-analysis of the long-term outcomes from the first-generation Absorb bioresorbable vascular scaffold (BVS) showed that this period of excess risk ended at 3 years. Therefore, current attention has been focused on improving early outcomes by increasing the scaffold's tensile strength and reducing strut thickness.Areas covered: This review summaries the lessons learned from the first-generation BRS. It updates the long-term clinical outcomes of trials evaluating the ABSORB BVS and metallic alloy-based BRS. In addition, it reviews the next-generation BRSs manufactured in Asia.Expert opinion: Critical areas to improve the performance and safety of biodegradable scaffolds include further development in material science, surface modification, delivery systems, and long-term follow-up studies.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"391-407"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In-hospital cardiac arrest after STEMI: prevention strategies and post-arrest care. STEMI 后院内心脏骤停：预防策略和骤停后护理。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-30 DOI: 10.1080/14779072.2024.2383648

Walker Boyd, Wesley Young, Mehmet Yildiz, Timothy D Henry, Kari Gorder

引用次数: 0

Current status and future directions in artificial intelligence for nuclear cardiology. 核心脏病学人工智能的现状和未来方向。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-16 DOI: 10.1080/14779072.2024.2380764

Robert J H Miller, Piotr J Slomka

{"title":"Current status and future directions in artificial intelligence for nuclear cardiology.","authors":"Robert J H Miller, Piotr J Slomka","doi":"10.1080/14779072.2024.2380764","DOIUrl":"10.1080/14779072.2024.2380764","url":null,"abstract":"Introduction: Myocardial perfusion imaging (MPI) is one of the most commonly ordered cardiac imaging tests. Accurate motion correction, image registration, and reconstruction are critical for high-quality imaging, but this can be technically challenging and has traditionally relied on expert manual processing. With accurate processing, there is a rich variety of clinical, stress, functional, and anatomic data that can be integrated to guide patient management.Areas covered: PubMed and Google Scholar were reviewed for articles related to artificial intelligence in nuclear cardiology published between 2020 and 2024. We will outline the prominent roles for artificial intelligence (AI) solutions to provide motion correction, image registration, and reconstruction. We will review the role for AI in extracting anatomic data for hybrid MPI which is otherwise neglected. Lastly, we will discuss AI methods to integrate the wealth of data to improve disease diagnosis or risk stratification.Expert opinion: There is growing evidence that AI will transform the performance of MPI by automating and improving on aspects of image acquisition and reconstruction. Physicians and researchers will need to understand the potential strengths of AI in order to benefit from the full clinical utility of MPI.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"367-378"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141598956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipoprotein(a) in interventional cardiology: identifying patients at highest risk of recurrent cardiovascular events through early recognition - a case based review. 介入心脏病学中的脂蛋白（a）：通过早期识别确定复发性心血管事件风险最高的患者--基于病例的回顾。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-08-01 Epub Date: 2024-09-11 DOI: 10.1080/14779072.2024.2387678

Mick P L Renkens, Casper F Coerkamp, Lars S Witte, Shabiga Sivanesan, Nick S Nurmohamed, Marit Westerterp, Patrick Serruys, Yoshinobu Onuma, Maik J Grundeken, Deborah N Kalkman, Marcel Beijk, Marije M Vis, José P S Henriques, Ronak Delewi, Erik Stroes, Joanna J Wykrzykowska, Robbert J de Winter, Bimmer E P M Claessen

{"title":"Lipoprotein(a) in interventional cardiology: identifying patients at highest risk of recurrent cardiovascular events through early recognition - a case based review.","authors":"Mick P L Renkens, Casper F Coerkamp, Lars S Witte, Shabiga Sivanesan, Nick S Nurmohamed, Marit Westerterp, Patrick Serruys, Yoshinobu Onuma, Maik J Grundeken, Deborah N Kalkman, Marcel Beijk, Marije M Vis, José P S Henriques, Ronak Delewi, Erik Stroes, Joanna J Wykrzykowska, Robbert J de Winter, Bimmer E P M Claessen","doi":"10.1080/14779072.2024.2387678","DOIUrl":"10.1080/14779072.2024.2387678","url":null,"abstract":"Introduction: Lipoprotein(a) [Lp(a)] is linked to higher risks of atherosclerotic cardiovascular disease (ASCVD). Current guideline recommendations are quite liberal on measuring Lp(a) (Class IIa, Level C), and may lead to underuse among (interventional) cardiologists.Areas covered: This case-based narrative review outlines four clinical cases of patients with elevated Lp(a) to illustrate its pathophysiological impact on coronary artery disease (CAD). The expert consensus statements from the American Heart Association (AHA) and European Atherosclerosis Society (EAS) served as the basis of this review. More recent publications, from 2023 to 2024, were accessed through the MEDLINE online library.Expert opinion: We highlighted the importance of routine Lp(a) measurement in identifying patients at high risk for atherosclerosis, necessitating potent risk mitigation. Measuring Lp(a) helps clinicians identify which patients are at highest residual risk, who require potent pharmacological treatment and special attention during catheter interventions. As noninvasive and advanced intravascular imaging modalities evolve, future catheterization laboratories will integrate advanced imaging, diagnostics, and treatment, facilitating tailored patient care. Knowing Lp(a) levels is crucial in this context. While Lp(a)-lowering drugs are currently investigated in clinical trials, it is of paramount importance to know Lp(a) levels and strive toward aggressive management of other modifiable risk factors in patients with elevated Lp(a) and established symptomatic CAD being diagnosed or treated in catheterization laboratories.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":"22 8","pages":"353-366"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cerebral embolic protection for stroke prevention during transcatheter aortic valve replacement. 经导管主动脉瓣置换术中预防中风的脑栓塞保护。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-08-01 Epub Date: 2024-08-02 DOI: 10.1080/14779072.2024.2385989

Jawad Basit, Mushood Ahmed, George Kidess, Zaofashan Zaheer, Laveeza Fatima, Hamza Naveed, Mohammad Hamza, Maurish Fatima, Aman Goyal, Pranav Loyalka, Mahboob Alam, M Chadi Alraies

{"title":"Cerebral embolic protection for stroke prevention during transcatheter aortic valve replacement.","authors":"Jawad Basit, Mushood Ahmed, George Kidess, Zaofashan Zaheer, Laveeza Fatima, Hamza Naveed, Mohammad Hamza, Maurish Fatima, Aman Goyal, Pranav Loyalka, Mahboob Alam, M Chadi Alraies","doi":"10.1080/14779072.2024.2385989","DOIUrl":"10.1080/14779072.2024.2385989","url":null,"abstract":"Introduction: Cerebral Embolic Protection Device (CEPD) captures emboli during Transcatheter Aortic Valve Replacement (TAVR). With recently published pivotal trials and multiple cohort studies reporting new data, there is a need to re-calibrate available statistical evidence.Methods: A systematic literature search was conducted across databases from inception till February 2023. Dichotomous outcomes were pooled using Odds Ratio (OR), while continuous outcomes were pooled using Standardized Mean Difference (SMD) along with 95% corresponding intervals (95% CIs).Results: Data was included from 17 studies (7 RCTs, 10 cohorts, n = 155,829). Use of CEPD was associated with significantly reduced odds of stroke (OR = 0.60, 95% CI = 0.43-0.85, p = 0.003). There was no significant difference in disabling stroke (p = 0.25), non-disabling stroke (p = 0.72), and 30-day mortality (p = 0.10) between the two groups. There were no significant differences between the two groups for Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) findings, acute kidney injury, risk of pacemaker implantation life-threatening bleed, major bleed, minor bleed, worsening National Institute of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS) and vascular complications (p > 0.05).Conclusions: The use of CEPD during TAVR reduced the incidence of all-stroke (p = 0.003); however, there were no significant differences in any of the other pooled outcomes (p > 0.05).Registration: The protocol of this meta-analysis was registered with the Open Science framework [https://doi.org/10.17605/OSF.IO/7W564] before data acquisition was started.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"409-420"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0